Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

• Status: Unknown status
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the impact of adjunctive cilostazol on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Treatments: Aspirin; Cilostazol; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

1. The patient must be at least 18 years of age

2. Significant coronary artery stenosis (> 70% by visual estimate)

3. Elective coronary stent implantation

Exclusion Criteria:

1. Acute myocardial infarction

2. Hemodynamic instability active bleeding and bleeding diatheses

3. Oral anticoagulation therapy with warfarin,use of peri-procedural glycoprotein IIb/IIIa inhibitors

4. Contraindication to antiplatelet therapy

5. Left ventricular ejection fraction < 30%

6. Leukocyte count < 3,000/mm3, platelet count < 100,000/mm3

7. AST or ALT ≥ 3 times upper normal

8. Serum creatinine level ≥ 2.5 mg/dL

9. stroke within 3 months

10. Noncardiac disease with a life expectancy < 1 year

11. Inability to follow the protocol